ENTA Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 4.81%, SMA50 2.94%, SMA200 39.67%). The stock’s 14-day RSI is 57.61 (neutral), while the ATR of 0.78 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -15.98% below its high and over 252.32% above its low. Average 10-day trading volume of 163.22 thousand shares is in line with the 3-month average of 168.21 thousand, indicating normal recent market interest.

Enanta Pharmaceuticals, Inc. has 21.38 million shares outstanding. The public float is 14.25 million shares, elevated short interest at 13.57% of float. This equals 2.73 million shares. The short ratio is 15.18 days. Institutional investors hold 92.65% of the float. Insiders own 6.55%. Luly Jay R. holds 858.03 thousand shares, Or Yat Sun has 371.39 thousand shares and MELLETT PAUL J has 91.71 thousand shares.

Enanta Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$7.91. This means the shares are trading below this model’s fair value.

Enanta Pharmaceuticals, Inc. generated EPS of -$3.20 over the past year. Five-year average earnings growth is -16.17%. Wall Street analysts project EPS growth of 17.2% annually over the next five years. The latest quarter delivered EPS of -$0.45. The next quarter is forecast at -$0.56. Next year's EPS is expected at $5.54. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $28.00 to $12.00. The high target offers 131.98% upside. The low target suggests -0.58% downside. The mean target is $20.75. This offers 71.91% upside. Enanta Pharmaceuticals, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 11, 2026, missed forecasts by -2.17%. The prior quarter beat by -22.22%. Over the last six quarters, Apple has recorded several small beats. These include -9.48% in February 10, 2025.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) closed at $12.07 USD, gaining $0.63 (5.51%) from the previous close of $11.44. The stock is currently mid-range between its 52-week high and low $6.43 and $17.15. With a market capitalization of about $280.22 million, Enanta Pharmaceuticals, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.99). Key stats such as the average daily volume over the past year has been around 168.48 thousand shares, in line with its 52-week average. Headquartered in Watertown, MA, Enanta Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jay R. Luly, the company employs approximately 131 people and listed since March 21, 2013. Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions.

Enanta Pharmaceuticals, Inc. trades at a P/E ratio of -4.12, slightly below the S&P 500 average, with a price-to-sales ratio of 4.01 and a price-to-book ratio of 2.19 suggesting the stock is closer to book value. The P/FCF stands at -28.88, also below market averages.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares are down -20.8% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Enanta Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -4.12. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $44.81, suggesting 271.25% upside. Our AI forecast model points to short-term weakness (-17.23% over two weeks), a medium-term rise (15.66% over three months), and a longer-term gain (143.33% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Enanta Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -17.23%, with price expected at $9.99 by June 29, 2026, within a range of $9.36 to $10.62 3-Month Outlook: Projected rise of 15.66%, reaching $13.96 by September 11, 2026, with a range of $12.37 to $15.50. 1-Year Outlook: Projected gain of 143.33%, with price at $29.37 by June 15, 2027, within a range of $21.11 to $39.82.